Crizanlizumab

Last Updated: 09/19/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 150 publications

crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.

crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.

Journal: Blood. Red cells & iron

Published: August 30, 2026

Association between comorbid depression, antidepressant adherence, and disease-modifying therapy adherence among Texas Medicaid patients with sickle cell disease.

Association between comorbid depression, antidepressant adherence, and disease-modifying therapy adherence among Texas Medicaid patients with sickle cell disease.

Journal: Journal of managed care & specialty pharmacy

Published: June 24, 2026

Benefit-Risk of Voxelotor, Crizanlizumab, and L-Glutamine in Sickle Cell Disease: A Systematic Review.

Benefit-Risk of Voxelotor, Crizanlizumab, and L-Glutamine in Sickle Cell Disease: A Systematic Review.

Journal: The American journal of the medical sciences

Published: June 17, 2026

Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway.

Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway.

Journal: Cancer research communications

Published: May 19, 2026

A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).

A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).

Journal: American journal of hematology

Published: February 11, 2026

Rethinking Sickle Cell Disease as a Systemic Vasculopathy.

Rethinking Sickle Cell Disease as a Systemic Vasculopathy.

Journal: Cells

Published: January 02, 2026

Optimizing the right time to start sickle cell therapies.

Optimizing the right time to start sickle cell therapies.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US.

Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US.

Journal: Journal of comparative effectiveness research

Published: November 24, 2025

The Role of Pediatric Clinicians in the Diagnosis, Management, and Referral of Priapism in Children and Adolescents with Sickle Cell Disease.

The Role of Pediatric Clinicians in the Diagnosis, Management, and Referral of Priapism in Children and Adolescents with Sickle Cell Disease.

Journal: Pediatric clinics of North America

Published: November 09, 2025

Low Use of FDA-Approved Medications for Sickle Cell Disease in Adults.

Low Use of FDA-Approved Medications for Sickle Cell Disease in Adults.

Journal: European journal of haematology

Published: October 23, 2025

Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy.

Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy.

Journal: Cureus

Published: October 21, 2025

Spleen Tyrosine Kinase Inhibition Mitigates Hemin-Induced Thromboinflammation in an Organ-Specific Manner in Sickle Cell Mice.

Spleen Tyrosine Kinase Inhibition Mitigates Hemin-Induced Thromboinflammation in an Organ-Specific Manner in Sickle Cell Mice.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: August 15, 2025

Showing 1-12 of 150

Last Updated: 09/19/2026